Use of antivascular endothelial growth factor for diabetic macular edema

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 493-517

  Karim, Rushmia ^a   Tang, Benjamin ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Anti VEGF; Avastin ; Diabetic macular edema; Pegaptanib; Ranizubimab

Indexed keywords

EID: 77956096073     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/opth.s8980     Document Type: Article

References (33)

1. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142:961-969.
2. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin®) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007;114:743-750.
3. Grover D, Li TJ, Chong CCW. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008;(1):CD005656.
4. Mitchell P, Foran S. Guidelines for the Management of Diabetic Retinopathy. The National Health and Medical Research Council (NHMRC). Canberra, Australia: Australian Diabetes Society for the Department of Health and Aging. 2008.
5. Soliman W, Vinten M, Sander B, et al. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular edema. Acta Opthalmol. 2008;86:365-371.
6. Fong DS, Ferris FL, Davis MD, Chew EY. The Early Treatment of Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS Report No 1. Arch Ophthalmol. 1985;103:1644-1652.
7. Thomas D, Bunce C, Moorman C, Laidlaw DA. A randomised controlled feasibility trial of vitrectomy versus laser for diabetic macular edema. Br J Ophthalmol. 2005;89:81-86.
8. Jain RK. The VEGF ligand and angiogenesis. Science. 2005;307: 58-62.
9. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Eng J Med. 1994;331:1480-1487.
10. Emerson MV, Lauer AK. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs. 2007;21:245-257.
11. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5:123-132.
12. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin®) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275-278.
13. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cance Control. 2007;14:285-294.
14. Vedula SS, krystolik M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2008;2:21-62.
15. Chung EJ, Roh MI, Kwon OW, Koh HJ. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina. 2008;28:957-963.
16. US National Institute of Health Clinical Trials register. Available from: www.clinicaltrials.gov. Accessed Jan 10, 2010.
17. Current Controlled Trials register. Available from: http://www.controlled-trials.com. Accessed Jan 10, 2010.
18. The National Research Register (NRR). National Institute of Health Research, National Health System. Available from: www.nrr.nhs.uk.
19. Cochrane Handbook for Systematic Reviews of Interventions 6.7. San Francisco, CA: The Cochrane Collaboration, 2006.
20. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2008;246:483-489.
21. Cunningham ET Jr, Adamis AP, Altaweel M, et al. Macugen diabetic retinopathy study group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747-1757.
22. Scott IU, Bressler NM, Bressler SB, et al. Diabetic retinopathy clinical research network study group. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina. 2008;28:36-40.
23. Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitreal bevacizumab (Avastin®) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina. 2007;27:1187-1195.
24. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular edema (IBEME study). Br J Ophthalmol. 2008;92:76-80.
25. Rizzo S, Genovesi-Ebert F, Dibartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin®) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clini Exp Ophthalmol. 2008;246:837-842.
26. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142:961-969.
27. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin®) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Multicenter Study. Ophthalmology. 2007;114:743-750.
28. Byeon SH, Kwon YA, Oh HS, Kim M, Kwon OW. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. J Ocul Pharmacol Ther. 2007;23:387-394.
29. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin®) for diabetic macular edema in previously vitrectomized eyes. Am J of Ophthalmol. 2007;144:124-126.
30. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol. 2008;145:854-861.
31. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin®) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999-1005.
32. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with centerinvolving clinically significant diabetic macular edema. Ophthalmology. 2006;113:1706-1712.
33. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611.